NOVN.CH

105.28

+0.96%↑

LONN.CH

547.8

+1.97%↑

SDZ.CH

46.43

+2.95%↑

STMN.CH

88.06

+0.48%↑

BANB.CH

58.05

-1.44%↓

NOVN.CH

105.28

+0.96%↑

LONN.CH

547.8

+1.97%↑

SDZ.CH

46.43

+2.95%↑

STMN.CH

88.06

+0.48%↑

BANB.CH

58.05

-1.44%↓

NOVN.CH

105.28

+0.96%↑

LONN.CH

547.8

+1.97%↑

SDZ.CH

46.43

+2.95%↑

STMN.CH

88.06

+0.48%↑

BANB.CH

58.05

-1.44%↓

NOVN.CH

105.28

+0.96%↑

LONN.CH

547.8

+1.97%↑

SDZ.CH

46.43

+2.95%↑

STMN.CH

88.06

+0.48%↑

BANB.CH

58.05

-1.44%↓

NOVN.CH

105.28

+0.96%↑

LONN.CH

547.8

+1.97%↑

SDZ.CH

46.43

+2.95%↑

STMN.CH

88.06

+0.48%↑

BANB.CH

58.05

-1.44%↓

Search

Roche Holding AG

Abierto

SectorSanidad

301 0.47

Resumen

Variación precio

24h

Actual

Mínimo

297.2

Máximo

303.2

Métricas clave

By Trading Economics

Ingresos

1.7B

3.7B

Ventas

-15B

16B

P/B

Media del Sector

22.865

35.739

Rentabilidad por dividendo

3.62

Margen de beneficios

23.266

Empleados

103,249

EBITDA

547M

6.5B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.62%

3.08%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-368M

205B

Apertura anterior

300.53

Cierre anterior

301

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 371 Clasificación en Healthcare

Roche Holding AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 sept 2025, 14:01 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 sept 2025, 10:05 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

89bio Shares Soar Premarket on Takeover by Roche

18 sept 2025, 10:04 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 sept 2025, 05:37 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy 89bio for Up to $3.5 Billion

24 jul 2025, 15:09 UTC

Ganancias

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices -- Update

24 jul 2025, 05:36 UTC

Ganancias

Roche Backs 2025 Views After Strong Sales of Key Drugs

1 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 oct 2025, 09:05 UTC

Acciones populares

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 sept 2025, 14:12 UTC

Adquisiciones, fusiones, absorciones

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 sept 2025, 07:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 sept 2025, 05:09 UTC

Adquisiciones, fusiones, absorciones

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 sept 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Roche: Deal Is Expected to Close in 4Q

18 sept 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 sept 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 sept 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 sept 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 sept 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Roche: Total Deal Value Is Up to $3.5B

18 sept 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy 89bio

18 sept 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Roche Enters Into Deal to Buy 89bio

8 ago 2025, 10:51 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

8 ago 2025, 07:39 UTC

Charlas de Mercado
Ganancias

Roche Could Reach Peak Earnings Growth This Year -- Market Talk

5 ago 2025, 10:40 UTC

Charlas de Mercado

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

24 jul 2025, 06:52 UTC

Charlas de Mercado
Ganancias

Roche Looks Confident in a Tricky Environment -- Market Talk

24 jul 2025, 05:05 UTC

Ganancias

Roche Backs 2025 View

24 jul 2025, 05:05 UTC

Ganancias

Correct: Roche 1H Diagnostics Sales Down 3%, Reported

24 jul 2025, 05:04 UTC

Ganancias

Correct: Roche 1H Sales Rose 4% On Year , Reported

24 jul 2025, 05:04 UTC

Ganancias

Roche 1H Net Pft Was Seen at CHF8.4B

24 jul 2025, 05:04 UTC

Ganancias

Roche 1H Net Pft CHF7.8B

24 jul 2025, 05:03 UTC

Ganancias

Roche 1H Oper Pft CHF12.0B

Comparación entre iguales

Cambio de precio

Roche Holding AG previsión

Sentimiento

By Acuity

149 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat